Pfizer’s patent on LYRICA, an anti-epileptic drug used to treat fibromyalgia or nerve pain, has been extended until June 30, 2019. For Preferred Medical, LYRICA is number eight in utilization and number one in cost. One reason for LYRICA’s high usage is the search for an alternative to opioids to treat chronic pain. Any claims currently using LYRICA will see higher name-brand pricing into the foreseeable future.
To see the rest of the article and learn why this matters, enter your information below.